Novel therapeutic platforms usually go through the phases of initial enthusiasm, followed by a trough of disappointment to meet the initial hype, and then after years of solving the technical challenges commercial clinical success is achieved.  

Nucleic acids drugs targeting RNA and the genome provide excellent examples of these cycles. 

Tod Woolf (Technology Licensing Officer) will describe work of his biotech teams and other biotechs in the area of antisense, RNAi and therapeutic editing that reflect phases of these boom bust cycles, with an emphasis on how chemical modification of nucleic acid drugs contributed to the enablement of nucleic acid therapeutic platforms.

This session is part of the Intellectual Property Lunch and Learn Series co-sponsored by the MIT Libraries and the Technology Licensing Office. 

To register for this event please contact Katrina Khalil via email: kmkhalil@mit.edu